Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01171820
Other study ID # 05-369 Diabetic Sub-study
Secondary ID
Status Completed
Phase Phase 4
First received April 1, 2010
Last updated October 1, 2010
Start date November 2006
Est. completion date July 2010

Study information

Verified date October 2010
Source Abbott Vascular
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery lesions in patients (Diabetic sub-study).


Description:

The SPIRIT V Clinical Evaluation consists of two concurrent studies,the Diabetic sub-study and the Registry.

The SPIRIT V Diabetic sub-study is a prospective, randomized, active-controlled, single blind, parallel two-arm multi-center study comparing the XIENCE V® EECSS to the TAXUS® Liberté™ in the treatment of diabetic patients with coronary artery lesions who will fulfill the eligibility criteria. Approximately 300 patients will be randomized (2:1) against the TAXUS® Liberté™ coronary stent system. These patients will be recruited in up to 40 selected sites.

The long term safety and efficacy of the XIENCE V EECSS have been demonstrated in the SPIRIT FIRST trial up to 5 years, the SPIRIT II trial up to 4 years, and in the SPIRIT III Randomized Control Trial (RCT) up to 3 years. In addition, these pre-approval studies have shown low rates of Target Vessel Failure and Major Adverse Cardiac Events (MACE) that were observed to plateau or gradually decline after about 1 year and were consistently lower than the comparator arm of each study. This benefit in MACE is sustained for up to 5 years and is also independent of the first year results.

The post approval SPIRIT V study demonstrated that the use of the XIENCE EECSS in complex lesions in a real-world population resulted in 1 year MACE, Stent Thrombosis and Target Lesion Revascularization rates that are comparable to those of the previously mentioned pre-approval studies which included patients with more restricted inclusion / exclusion criteria.

Therefore, based on existing data from these trials, Abbott Vascular has decided to discontinue further follow up in the SPIRIT V Diabetic study after 1 year.


Recruitment information / eligibility

Status Completed
Enrollment 324
Est. completion date July 2010
Est. primary completion date July 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- at least 18 years

- able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the XIENCE V® EECSS and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure, as approved by the appropriate Medical Ethics Committee of the respective clinical site

- diagnosed with diabetes, as documented by medical history.

- evidence of myocardial ischemia

- acceptable candidate for CABG surgery

- agree to undergo all CIP-required follow-up examinations

- artery morphology and disease is suitable to be optimally treated with a maximum of 4 planned stents

- maximum of one, de novo, target lesion per native major epicardial vessel or side branch

- target vessel reference diameter must be between 2.25 mm and 4.0 mm by visual estimate

- target lesion = 28 mm in length by visual estimate

- target lesion must be in a major artery or branch with a visually estimated stenosis of > 50% and < 100% and a TIMI flow > 1

Exclusion Criteria:

- known diagnosis of AMI within 72 hours preceding the index procedure

- current unstable arrhythmias

- LVEF < 30%

- received a heart or any other organ transplant or is on a waiting list for any organ transplant

- receiving or scheduled to receive chemotherapy or radiation therapy within 30 days prior to or after the procedure.

- receiving immunosuppression therapy or has known immunosuppressive or autoimmune disease

- known hypersensitivity or contraindication to specific agents

- elective surgery is planned within the first 9 months after the procedure that will require discontinuing either aspirin or clopidogrel

- platelet count limits, WBC limits or documented or suspected liver disease

- renal insufficiency

- history of bleeding diathesis or coagulopathy or will refuse blood transfusions

- CVA or TIA within the past 6 months

- significant GI or urinary bleed within the past 6 months

- history of other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse that may cause non-compliance with the CIP, confound the data interpretation or is associated with a limited life expectancy (i.e. less than one year)

Target lesion meets any of the following criteria:

- In-stent restenotic

- aorto-ostial location (within 3 mm)

- left main location

- located within 2 mm of the origin of the LAD or LCX

- located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft (defined as vessel irregularity per angiogram and > 20% stenosed lesion by visual estimation)

- lesion involving a side branch = 2.5 mm in diameter

- lesion involving a side branch with > 50% stenosis by visual estimation Lesion involving a side branch requiring predilatation

- located in a major epicardial vessel that has been previously treated with brachytherapy

- located in a major epicardial vessel or a side branch that has been previously treated with any type of percutaneous intervention (e.g., balloon angioplasty, cutting balloon, atherectomy), < 9 months prior to the index procedure

- total occlusion (TIMI flow 0), prior to wire crossing

- excessive tortuosity proximal to or within the lesion

- extreme angulation (= 90%) proximal to or within the lesion

- heavy calcification

The target vessel contains visible thrombus

Patient has a high probability that a procedure other than pre-dilatation, stenting and post-dilatation will be required at the time of index procedure for treatment of the target vessel (e.g. brachytherapy)

Patient has additional clinically significant lesion(s) (> 50% diameter stenosis) in a target vessel or side branch for which an intervention within 9 months after the index procedure may be required

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Intervention

Device:
TAXUS® Liberté™
Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
XIENCE V® EECSS
Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes

Locations

Country Name City State
Austria Salzburger Landeskliniken Salzburg
France C.H.U. - Hopital Michallon Grenoble
France CHU Lille - Hôpital Cardiologique Lille
Germany Herzzentrum Bernau
Germany Universitätsklinikum Heidelberg
Germany Lukas Krankenhaus Neuss Neuss
Germany Herzzentrum Siegburg GmbH Siegburg
Israel Sheba Medical Center Ramat Gan
Italy Azienda Ospedaliera Riuniti Bergamo
Italy Ospedale Civile Mirano
Italy Azienda Ospedaliera di Padova Padova
Italy IRCCS Policlinico San Matteo Pavia
Italy Azienda Ospedaliera S. Gdi Dio Salerno Salerno
Malaysia Institute Jantung Negara Kuala Lumpur
Netherlands Medisch Centrum Alkmaar Alkmaar
Netherlands Maasstad Ziekenhuis Rotterdam
Poland Medical University of Bydgoszcz Bydgoszcz
Spain General De Alicante Alicante
Spain Hospital Belvigte de Barcelona Barcelona
Spain Hospital Santa Creu I Sant Pau Barcelona
Spain Clinico San Carlos Madrid
Spain Hospital Puerta de Hierro Madrid
Spain La Paz Madrid
Spain Hospital Virgen de la Arrixaca Murcia
Spain Hospital General de Valencia Valencia
Thailand King Chulalongkorn Memorial Hospital Bangkok
United Kingdom King's College Hospital London
United Kingdom Wessex Cardiac Unit Southampton

Sponsors (1)

Lead Sponsor Collaborator
Abbott Vascular

Countries where clinical trial is conducted

Austria,  France,  Germany,  Israel,  Italy,  Malaysia,  Netherlands,  Poland,  Spain,  Thailand,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary In-stent Late Loss(LL) In-stent minimal lumen diameter (MLD) post-procedure minus (-) in-stent MLD at follow-up 270 days No
Secondary Clinical Device Success Successful delivery and deployment of the study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stent) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable), without use of a device outside the assigned treatment strategy. Acute: At time of index procedure No
Secondary Clinical Procedure Success Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of cardiac death, MI attributed to the target vessel and/or CI-TLR during the hospital stay with a maximum of first seven days post index procedure. In multiple lesion setting each lesion must meet clinical procedure success. Acute: At time of index procedure Yes
Secondary In-segment Late Loss In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at follow-up 270 days No
Secondary Proximal Late Loss Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up 270 day No
Secondary Distal Late Loss Distal Minimum Lumen Diameter (MLD) post-procedure minus distal MLD at follow-up 270 days No
Secondary In-stent Angiographic Binary Restenosis Rate Percent of patients with a follow-up percent diameter stenosis of = 50% per Quantitative Coronary Angiogram. 270 days No
Secondary In-segment Angiographic Binary Restenosis Rate Percent of patients with a follow-up percent diameter stenosis of = 50% per Quantitative Coronary Angiogram. 270 days No
Secondary In-stent Percent Diameter Stenosis This number represents the average of percent diameter stenosis found on examination of all the lesions analyzed.
This value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiogram.
270 days No
Secondary In-segment Percent Diameter Stenosis This number represents the average of percent diameter stenosis found on examination of all the lesions analyzed.
This value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiogram.
270 days No
Secondary Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible) A thrombosis is blood clot that forms on the stent. This outcome measures the percentage of participants found to have this condition. 30 days Yes
Secondary Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible) A thrombosis is blood clot that forms on the stent 240 days Yes
Secondary Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible) A thrombosis is blood clot that forms on the stent 1 year Yes
Secondary Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated. 30 days Yes
Secondary Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated. 240 days Yes
Secondary Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated. 1 year Yes
Secondary Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR) 30 days Yes
Secondary Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR) 240 days Yes
Secondary Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR) 1 year Yes
Secondary Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR) 30 days Yes
Secondary Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR) 240 days Yes
Secondary Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR) 1 year Yes
Secondary Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR) 30 days Yes
Secondary Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR) 240 days Yes
Secondary Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR) 1 year Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A

External Links